Dyspepsia and indigestion on Zepbound, Wegovy, Mounjaro and other GLP-1 medicines
The short answer
Zepbound indigestion, which the label calls dyspepsia, was reported by 9% to 10% of adults against 4% on placebo. Dyspepsia is in the tables of six GLP-1 labels, including 9% on Wegovy 2.4 mg against 3%. The Ozempic and Rybelsus labels report it in text, below their table cutoff. Tell your prescriber about indigestion that persists or follows each dose increase.
Key takeaways
- Dyspepsia is the label word for indigestion. Six GLP-1 labels list it in their tables.
- Tell your prescriber if indigestion or bloating persists, worsens after a dose increase, or limits what you eat and drink.
- Seek prompt medical attention for severe or persistent abdominal pain.
- Ask a pharmacist before taking an antacid or acid reducer alongside your other medicines.
How often it was reported in the label's trials
| Reaction | Placebon=958 | 5 mgn=630 | 10 mgn=948 | 15 mgn=941 |
|---|---|---|---|---|
| Dyspepsia | 4% | 9% | 9% | 10% |
| Reaction | Placebon=235 | 5 mgn=237 | 10 mgn=240 | 15 mgn=241 |
|---|---|---|---|---|
| Dyspepsia | 3% | 8% | 8% | 5% |
| Reaction | Placebon=1261 | Wegovy injection 2.4 mg once weeklyn=2116 |
|---|---|---|
| Dyspepsia | 3% | 9% |
| Reaction | Placebon=1576 | 5.5 mgn=1051 | 9 mgn=1055 | 17.2 mgn=1049 |
|---|---|---|---|---|
| Dyspepsia | 4% | 12% | 16% | 13% |
| Reaction | Placebon=1941 | Saxendan=3384 |
|---|---|---|
| Dyspepsia | 2.7% | 9.6% |
| Reaction | Placebon=126 | Saxendan=125 |
|---|---|---|
| Dyspepsia | 2.4% | 4% |
| Reaction | Placebon=568 | 0.75 mgn=836 | 1.5 mgn=834 |
|---|---|---|---|
| Dyspepsia | 2.3% | 4.1% | 5.8% |
| Reaction | 1.5 mgn=612 | 3 mgn=616 | 4.5 mgn=614 |
|---|---|---|---|
| Dyspepsia | 2.8% | 5% | 2.6% |
Each medicine's figures come from its own trials, which differ in dose, length and who took part. They are not a head-to-head comparison.
If you have indigestion, reflux or bloating on a GLP-1 medicine, tell your prescriber if it persists, if it worsens after a dose increase, or if it affects how much you can eat and drink. Seek prompt medical attention for severe or persistent abdominal pain.
Dyspepsia is the label word for indigestion. Six of the eight GLP-1 labels give it a row in their tables of common reactions, and the other two report it in text. The labels also list several close relatives (reflux, burping, bloating and gas) as separate rows, covered below.
Labels that list dyspepsia in their tables
Each figure is the share of trial patients who reported dyspepsia, next to the placebo group from the same trials. A placebo group gets an inactive treatment instead of the medicine.
- Foundayo (adults with obesity or overweight, two pooled trials): 12% at 5.5 mg, 16% at 9 mg and 13% at 17.2 mg, with 4% on placebo.
- Zepbound (adults with obesity or overweight, two pooled trials): 9% at 5 mg, 9% at 10 mg and 10% at 15 mg, with 4% on placebo.
- Saxenda (adults, five trials): 9.6%, with 2.7% on placebo. In adolescents aged 12 and older: 4%, with 2.4% on placebo.
- Wegovy 2.4 mg injection (adults, three weight reduction trials): 9%, with 3% on placebo.
- Mounjaro (adults with type 2 diabetes, two pooled trials): 8% at 5 mg, 8% at 10 mg and 5% at 15 mg, with 3% on placebo.
- Trulicity (adults with type 2 diabetes, pooled trials): 4.1% at 0.75 mg and 5.8% at 1.5 mg, with 2.3% on placebo. In the higher-dose trial with no placebo arm: 2.8% at 1.5 mg, 5.0% at 3 mg and 2.6% at 4.5 mg.
The highest dose group doesn’t always have the highest figure. In Mounjaro’s table, Foundayo’s and Trulicity’s higher-dose trial, a lower or middle group reported more dyspepsia than the top one. The labels don’t comment on this.
Dyspepsia isn’t listed in Wegovy’s table for the 7.2 mg dose, which includes only reactions more frequent on 7.2 mg than on both 2.4 mg and placebo. It isn’t in Wegovy’s adolescent table either.
Labels that report it below the table cutoff
Ozempic. The injection label’s table is limited to reactions reported by at least 5% of patients. Its text adds gastrointestinal (stomach and bowel) reactions with a frequency under 5%, listed as placebo, 0.5 mg and 1 mg: dyspepsia at 1.9%, 3.5% and 2.7%.
Rybelsus. The tablet label, which also covers Ozempic tablets, likewise lists dyspepsia among the gastrointestinal reactions that fall outside its table, each reported by 3% of patients or fewer. Dyspepsia isn’t listed in the Rybelsus table itself.
Reflux, burping, bloating and gas
Indigestion rarely arrives alone in these tables. The same labels report these as separate rows. Eructation is burping, flatulence is gas, abdominal distension is bloating, and reflux here means gastroesophageal reflux disease.
- Zepbound: gastroesophageal reflux disease at 4%, 4% and 5% across the 5 mg, 10 mg and 15 mg groups, with 2% on placebo; eructation at 4%, 5% and 5%, with 1% on placebo; flatulence and abdominal distension each at 3%, 3% and 4%, with 2% on placebo.
- Wegovy 2.4 mg: abdominal distension 7% (5% on placebo), eructation 7%, flatulence 6% (4%), reflux 5% (3%) and gastritis 4% (1%). For eructation the label shows the placebo figure only as below 1%.
- Foundayo: abdominal distension at 7%, 9% and 8% across its three dose groups, with 3% on placebo; eructation at 6%, 8% and 8%, with 1%; reflux at 6%, 6% and 7%, with 2%.
- Saxenda: reflux 4.7% (1.7% on placebo), eructation 4.5% (0.2%), abdominal distension 4.5% (3%) and flatulence 4% (2.5%).
- Mounjaro, in text, as placebo, 5 mg, 10 mg and 15 mg: eructation 0.4%, 3.0%, 2.5% and 3.3%; reflux 0.4%, 1.7%, 2.5% and 1.7%.
- Trulicity, in text, as placebo, 0.75 mg and 1.5 mg: reflux 0.5%, 1.7% and 2.0%; eructation 0.2%, 0.6% and 1.6%.
These rows overlap in the people they count, and the trials behind each label are separate. Read each medicine against its own placebo column. The figures don’t rank the medicines.
Timing and related warnings
The labels’ timing statements are about nausea, vomiting and diarrhea. Only Wegovy’s is wide enough to include dyspepsia: gastrointestinal reactions as a group “were most frequently reported during dosage escalation,” the weeks when the dose is being raised.
Every label warns that gastrointestinal reactions are sometimes severe and says the medicine is not recommended in people with severe gastroparesis (a stomach that empties very slowly). In Zepbound’s pooled trials, severe gastrointestinal reactions were reported by 1.7% of patients on 5 mg, 2.5% on 10 mg and 3.1% on 15 mg, against 1% on placebo.
Upper abdominal discomfort also overlaps with the symptom the labels use to describe pancreatitis, an inflammation of the pancreas: persistent or severe abdominal pain, sometimes radiating to the back. Indigestion that’s mild and comes and goes is what the tables describe. Pain that’s severe or doesn’t let up is a different matter, covered on the abdominal pain page.
When to contact your prescriber
Raise indigestion, reflux or bloating with your prescriber if it persists, if it worsens after a dose increase, or if it affects how much you can eat and drink. Seek prompt medical attention for severe or persistent abdominal pain. Leave dose decisions to your prescriber.
See also nausea, constipation and the side effects overview.
Frequently asked questions
What is dyspepsia?
Dyspepsia is the word the FDA labels use for indigestion, meaning discomfort in the upper abdomen around eating. The labels list it as its own row, separate from abdominal pain, gastroesophageal reflux disease (heartburn), eructation (burping), flatulence (gas) and abdominal distension (bloating). One person can report several of these, so you can't add the rows together.
Does Mounjaro cause indigestion?
Yes, dyspepsia is in the Mounjaro label's table. In two pooled placebo-controlled trials in adults with type 2 diabetes, 8% of patients on 5 mg, 8% on 10 mg and 5% on 15 mg reported it, compared with 3% on placebo. The label also reports burping, gas, reflux and bloating more often on Mounjaro than on placebo.
Does Ozempic cause heartburn or indigestion?
The Ozempic injection label reports both, below its table's cutoff. Dyspepsia was reported by 3.5% of patients on 0.5 mg and 2.7% on 1 mg, against 1.9% on placebo. Gastroesophageal reflux disease was reported by 1.9% and 1.5%, against 0% on placebo. These figures come from placebo-controlled trials in adults with type 2 diabetes.
When is indigestion on a GLP-1 a reason to call?
Tell your prescriber about indigestion that persists or follows each dose increase. Seek prompt medical attention for persistent or severe abdominal pain, sometimes radiating to the back, with or without vomiting, because the labels describe that as a sign of acute pancreatitis. Ask a pharmacist before taking an antacid or acid reducer alongside your other medicines.
Sources (8)
- 1.
- 2.
- 3.
- 4.
- 5.
- 6.
- 7.
- 8.
Related pages
- GLP-1 side effects: what the FDA labels report
- Abdominal pain on Wegovy, Zepbound, Ozempic and other GLP-1 medicines
- Ozempic nausea, Zepbound nausea and the other GLP-1 labels
- Ozempic constipation and constipation on other GLP-1 medicines
- Does Ozempic make you tired? Fatigue in the GLP-1 labels
- Does Ozempic cause hair loss? What the GLP-1 labels report
